-
公开(公告)号：EP3432931A1
公开(公告)日：2019-01-30
申请号：EP17721460.8
申请日：2017-03-27
-
公开(公告)号：EP3177610A4
公开(公告)日：2018-01-10
申请号：EP15829684
申请日：2015-08-07
IPC分类号： C07D401/14 , C07D401/04 , C07D471/16
CPC分类号： C07D401/14 , C07B2200/13 , C07D401/04 , C07D471/16
摘要： A process for preparing Nilotinib hydrochloride Form R5 and Form R6 comprises: step a) providing a solution of Nilotinib free base in acetic acid and optionally an organic solvent, step b) adding hydrochloric acid taken in an organic solvent to the solution of step a), then separating Nilotinib hydrochloride Form R5 (step c), and finally drying at about 100° C. to 150° C. to obtain Nilotinib hydrochloride Form R6.
-
93.发明授权SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS 有权选择性苯甲胺衍生物及其作为胆固醇酯转移蛋白抑制剂的应用
公开(公告)号：EP1981342B1
公开(公告)日：2016-11-30
申请号：EP06774300.5
申请日：2006-06-29
发明人： BARUAH, Anima , DE, Dibyendu , KHANNA, Ish Kumar , PILLARISETTI, Sivaram , ALEXANDER, Christopher W. , SREENU, Jennepali , MAITRA, Santanu , ALIKINJU, Shanavas
IPC分类号： A01N43/66 , A01N43/54 , A01N43/42 , A01N43/40 , A61K31/44 , A61K31/47 , C07D221/06 , C07D471/02 , C07D491/02 , C07D498/02 , C07D513/02 , C07D515/02 , C07D215/00 , C07D215/38 , C07D215/46 , C07D215/04 , C07D417/00 , C07D211/72 , C07D211/84 , C07D213/62 , C07D403/00
CPC分类号： C07D215/36 , C07D215/38 , C07D215/48 , C07D221/06 , C07D401/12 , C07D403/12 , C07D471/04
-
94.发明公开IN-VITRO METHOD FOR DETERMINING FATE OF POLYPEPTIDE VARIANT 审中-公开印度维多利亚州ZE BESTIMMUNG DES SCHICKSALS EINER POLYPEPTIVARIANTE
公开(公告)号：EP3058362A1
公开(公告)日：2016-08-24
申请号：EP14854678.1
申请日：2014-10-15
CPC分类号： G01N33/6854 , C07K16/065 , G01N33/68 , G01N2800/52
摘要： The present invention discloses an in-vitro method for determining the fate of protein variants upon administration to a subject. Also provided is a means for establishing comparability between two or more distinct therapeutically effective preparations of the same therapeutic protein.
摘要翻译： 本发明公开了一种用于在给予受试者时测定蛋白质变体的命运的体外方法。 还提供了用于在相同治疗性蛋白质的两种或更多种不同的治疗有效制剂之间建立可比性的手段。
-
公开(公告)号：EP2989090A2
公开(公告)日：2016-03-02
申请号：EP14787984.5
申请日：2014-04-23
IPC分类号： C07D401/14
CPC分类号： C07D401/14
摘要： Crystalline Forms R5, R5a, R5b and R6 of nilotinib hydrochloride and processes for their preparation.
摘要翻译： 盐酸尼洛替尼的结晶形式R5，R5a，R5b和R6及其制备方法。
-
公开(公告)号：EP2968575A1
公开(公告)日：2016-01-20
申请号：EP14717377.7
申请日：2014-03-17
发明人： OKUMU, Franklin , CHEN, Andrew X. , CHEN, Hailiang
IPC分类号： A61K47/24 , A61K9/107 , A61K31/196
CPC分类号： A61K9/1075 , A61K9/0019 , A61K31/196 , A61K45/06 , A61K47/24 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyperlipidemia, and (8) is neither hypoallergenic nor vein irritating.
-
公开(公告)号：EP2480197B1
公开(公告)日：2015-11-11
申请号：EP10743228.8
申请日：2010-06-17
CPC分类号： A61K31/4045 , A61K9/0043 , A61K31/40 , A61K31/404 , A61K31/70 , A61K31/7028 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
-
公开(公告)号：EP1706394B1
公开(公告)日：2014-12-17
申请号：EP04811264.3
申请日：2004-11-12
发明人： SUNDARAM, Venkataraman, Plot No 141, Flat No. 202 , MATHAD, Vijayavitthai Thippannachar , VENKAVALA, Pravinachandra Jayanthilal , ELATI, Chandrashekar Ravirama , KOLLA, Naveenkumar , GOVINDAN, Shanmugam , CHALAMALA, Subrahmanyeshwara Rao , GANGULA, Srinivas
IPC分类号： C07D307/87
CPC分类号： C07D307/87
-
99.发明公开SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS 有权替加利异丁烯酸酯VERBINDUNGEN ALS TROPOMYOSIN-REZEPTOR-KINASE-A（TRKA）-INHIBITOREN
公开(公告)号：EP2791139A1
公开(公告)日：2014-10-22
申请号：EP12834589.9
申请日：2012-12-12
发明人： SASMAL, Pradip, Kumar , AHMED, Shahadat , PRABHU, Ganesh , TEHIM, Ashok , PARADKAR, Vidyadhar , DATTATREYA, Marahanakuli, Prasanna , MAVINAHALLI, Nanjegowda, Jagadeesh
IPC分类号： C07D471/04 , A61K31/437 , A61P29/00 , A61P35/00 , C07D519/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/635 , C07D519/00 , Y02A50/414
摘要： The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
摘要翻译： 本申请涉及一系列取代的吡唑并[1,5-a]吡啶化合物，它们用作原肌球蛋白受体激酶（Trk）家族蛋白激酶抑制剂，制备方法和包含这些化合物的药物组合物。
-
100.发明公开5 - BENZYLAMINOMETHYL - 6 - AMINOPYRAZOLO [3, 4 -B]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER -TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS 有权5-苄基氨基甲基-6-氨基 - 吡唑并[3,4-b]吡啶衍生物作为胆甾醇酯 - TRANSFER-蛋白（CETP）抑制剂的动脉粥样硬化治疗的
公开(公告)号：EP2760864A1
公开(公告)日：2014-08-06
申请号：EP12816102.3
申请日：2012-09-27
发明人： BORUAH, Anima , ALIKUNJU, Shanavas
IPC分类号： C07D471/04 , A61K31/506 , A61K31/444 , A61K31/437 , A61P9/10
CPC分类号： C07D471/04
摘要： The present application relates to a series of substituted pyra-zolopyridin-6-amines having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. Wherein R, R1, R2, Ra, Raa, Rb and n are as defined herein. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I). The compounds of this application are useful as CETP inhibitors for increasing HDL cholesterol and decreasing LDL cholesterol in a patient.
摘要翻译： 本申请涉及一系列具有通式（I），包括其立体异构体和/或药学上可接受的盐及其substituiertem吡-zolopyridin -6- cardamines的。 其中R，R1，R2中，Ra，拉加，Rb和n如所定义。 本发明进一步涉及药物组合物，其包含式（I）的化合物。 本申请的化合物是作为CETP抑制剂的用于在患者中降低提高HDL胆固醇和LDL胆固醇是有用的。
-
-
-
-
-
-
-
-
-
搜索结果
248 条记录 (耗时 0.033 秒)
